[Experiences with timolol in treatment of glaucoma (author's transl)].
Timolol is a beta-adrenergic blocking agent that produces a significant decrease in intraocular pressure. Timolol ophthalmic solution 0,25% and 0,5% was compared to pilocarpine 1%, 2% and 4% in a randomized, double-masked study involving 40 patients with primary open angle glaucoma or ocular hypertension. Each patient was followed for 6 months. Timolol lowered the 1OP 30% compared to the pretreatment pressure, Pilocarpine 20%. Timolol was well tolerated in general, but 3 patients showed a superficial keratopathy. 30 other glaucoma patients with previously unsufficient pressure control received Timolol alone or in combination with a topical cholinergic agent or/and a systematic carbonic anhydrase inhibitor. The results are presented in detail.
D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004361:Drug Tolerance; D005500:Follow-Up Studies; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D010862:Pilocarpine / Q000627:therapeutic use; D011412:Propanolamines / Q000627:therapeutic use*; D013999:Timolol / Q000627:therapeutic use*
D011412:Propanolamines; D010862:Pilocarpine; D013999:Timolol
Erfahrungen mit Timolol in der Glaukomtherapie.